HK1050480A1 - Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions. - Google Patents

Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions.

Info

Publication number
HK1050480A1
HK1050480A1 HK03102619A HK03102619A HK1050480A1 HK 1050480 A1 HK1050480 A1 HK 1050480A1 HK 03102619 A HK03102619 A HK 03102619A HK 03102619 A HK03102619 A HK 03102619A HK 1050480 A1 HK1050480 A1 HK 1050480A1
Authority
HK
Hong Kong
Prior art keywords
quinazolines
dihydro
medicament
amino
treating
Prior art date
Application number
HK03102619A
Other languages
English (en)
Inventor
Andreas Weichert
Udo Albus
Hans-Willi Jansen
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of HK1050480A1 publication Critical patent/HK1050480A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03102619A 1999-10-27 2003-04-10 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions. HK1050480A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19951702A DE19951702A1 (de) 1999-10-27 1999-10-27 Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
PCT/EP2000/010127 WO2001030328A2 (de) 1999-10-27 2000-10-14 Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten

Publications (1)

Publication Number Publication Date
HK1050480A1 true HK1050480A1 (en) 2003-06-27

Family

ID=7927021

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102619A HK1050480A1 (en) 1999-10-27 2003-04-10 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions.

Country Status (28)

Country Link
US (1) US6331546B1 (xx)
EP (1) EP1244454B1 (xx)
JP (1) JP2003512420A (xx)
KR (1) KR20020041831A (xx)
CN (1) CN1181822C (xx)
AR (1) AR026242A1 (xx)
AT (1) ATE324111T1 (xx)
AU (1) AU7664800A (xx)
BR (1) BR0014985A (xx)
CA (1) CA2388965A1 (xx)
CZ (1) CZ20021414A3 (xx)
DE (2) DE19951702A1 (xx)
EE (1) EE200200215A (xx)
HK (1) HK1050480A1 (xx)
HR (1) HRP20020363A2 (xx)
HU (1) HUP0203774A3 (xx)
IL (1) IL149160A0 (xx)
MX (1) MXPA02004035A (xx)
NO (1) NO20021710D0 (xx)
NZ (1) NZ518588A (xx)
PL (1) PL356399A1 (xx)
RU (1) RU2002113667A (xx)
SK (1) SK5582002A3 (xx)
TR (1) TR200201141T2 (xx)
TW (1) TWI227135B (xx)
WO (1) WO2001030328A2 (xx)
YU (1) YU30602A (xx)
ZA (1) ZA200204057B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1109559B1 (en) * 1998-08-13 2005-10-26 Hadasit Medical Research Services & Development Co., Ltd. Inhibition of pathogenic processes related to tissue trauma
PL369313A1 (en) * 2001-12-05 2005-04-18 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560601A (en) 1968-11-25 1971-02-02 Ford Motor Co Process for manufacturing porous thermoplastic sheet material
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1994007498A1 (en) * 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Pharmaceutical composition for inhibiting tumor necrosis factor production
DE19713427A1 (de) * 1997-04-01 1998-10-08 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
HRP20020363A2 (en) 2004-02-29
US6331546B1 (en) 2001-12-18
NO20021710L (no) 2002-04-11
EE200200215A (et) 2003-06-16
WO2001030328A2 (de) 2001-05-03
PL356399A1 (en) 2004-06-28
HUP0203774A3 (en) 2003-07-28
TR200201141T2 (tr) 2002-11-21
HUP0203774A2 (en) 2003-05-28
BR0014985A (pt) 2003-07-22
ATE324111T1 (de) 2006-05-15
DE19951702A1 (de) 2001-05-03
NZ518588A (en) 2004-06-25
CN1181822C (zh) 2004-12-29
IL149160A0 (en) 2002-11-10
JP2003512420A (ja) 2003-04-02
CA2388965A1 (en) 2001-05-03
NO20021710D0 (no) 2002-04-11
TWI227135B (en) 2005-02-01
WO2001030328A3 (de) 2002-06-20
DE50012667D1 (de) 2006-06-01
SK5582002A3 (en) 2002-08-06
EP1244454A2 (de) 2002-10-02
CN1384747A (zh) 2002-12-11
EP1244454B1 (de) 2006-04-26
YU30602A (sh) 2004-12-31
ZA200204057B (en) 2003-02-26
RU2002113667A (ru) 2004-01-10
AR026242A1 (es) 2003-02-05
AU7664800A (en) 2001-05-08
CZ20021414A3 (cs) 2002-07-17
MXPA02004035A (es) 2002-10-11
KR20020041831A (ko) 2002-06-03

Similar Documents

Publication Publication Date Title
ZA200306234B (en) Phenethanolamine derivatives for treatment of respiratory diseases.
HK1087025A1 (en) Use of immunomudulatory compounds in preparation of a medicament for treating, preventing or managing myeloproliferative diseases
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
IL153508A0 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
MXPA03007349A (es) Derivados de xantina, su preparacion y su empleo como medicamentos.
ZA200305498B (en) Xanthine derivative, production and use thereof as a medicament.
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
IL210046A0 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
HK1079993A1 (en) Drugs for treating vascular diseases
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
ZA200306124B (en) Method of treating of demyelinating diseases or conditions.
HK1050480A1 (en) Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions.
IL142581A (en) Medicament for treating heart disease
WO2001060343A3 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
WO2005047278A3 (de) Substituierte dihydrochinazoline ii
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
EP1197225A4 (en) AGENTS FOR DISEASES CAUSED BY PTH OR PTHrH
HK1048938A1 (en) Use of 2-imidazolyl substituted carbinols for production of a medicament for treatment or prophylaxis of disease states as a result of ischaemic conditions.
ZA200205835B (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor.
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
AU1209501A (en) Method for treating parkinson's disease by administering (-)-5-keto-2-n,n-di-n-propylamino-tetrahydrotetralin

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20081014